Quantifying Life expectancy in people with Type 2 diabetes



Similar documents
Diabetes Complications

ADVANCE: a factorial randomised trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes

Cardiovascular Disease in Diabetes

Hormones and cardiovascular disease, what the Danish Nurse Cohort learned us

Insulin degludec (Tresiba) for the Management of Diabetes: Effectiveness, Value, and Value-Based Price Benchmarks

Understanding diabetes Do the recent trials help?

MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Main Effect of Screening for Coronary Artery Disease Using CT

Cardiovascular Effects of Drugs to Treat Diabetes

Managing diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)

DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study

Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires

Scottish Diabetes Survey Scottish Diabetes Survey Monitoring Group

Absolute cardiovascular disease risk assessment

Tips for surviving the analysis of survival data. Philip Twumasi-Ankrah, PhD

2012 Georgia Diabetes Burden Report: An Overview

Design and principal results

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting

Statins and Risk for Diabetes Mellitus. Background

EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA

Cohort Studies. Sukon Kanchanaraksa, PhD Johns Hopkins University

Scottish Diabetes Survey Scottish Diabetes Survey Monitoring Group

Therapeutic Approach in Patients with Diabetes and Coronary Artery Disease

Measure #1 (NQF 0059): Diabetes: Hemoglobin A1c Poor Control National Quality Strategy Domain: Effective Clinical Care

Scottish Diabetes Survey

The Link Between Obesity and Diabetes The Rapid Evolution and Positive Results of Bariatric Surgery

Underwriting Critical Illness Insurance: A model for coronary heart disease and stroke

International Task Force for Prevention Of Coronary Heart Disease. Clinical management of risk factors. coronary heart disease (CHD) and stroke

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study

Diabetes Brief. Pre diabetes occurs when glucose levels are elevated in the blood, but are not as high as someone who has diabetes.

PRESCRIBING GUIDELINES FOR LIPID LOWERING TREATMENTS for SECONDARY PREVENTION

Success factors in Behavioral Medicine

Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

How To Know If You Have Microalbuminuria

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

Fewer people with coronary heart disease are being diagnosed as compared to the expected figures.

Appendix: Description of the DIETRON model

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.

Facts about Diabetes in Massachusetts

Randomized trials versus observational studies

Epidemiology of Hypertension 陈 奕 希 李 禾 园 王 卓

Type 1 Diabetes ( Juvenile Diabetes)

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

Prognostic impact of uric acid in patients with stable coronary artery disease

Understanding Diseases and Treatments with Canadian Real-world Evidence

Big data size isn t enough! Irene Petersen, PhD Primary Care & Population Health

Racial and ethnic disparities in type 2 diabetes

Diabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus

Performance Measurement for the Medicare and Medicaid Eligible (MME) Population in Connecticut Survey Analysis

Maria Iachina, Anders Green, Erik Jakobsen, Anders Mellemgaard, Mark Krasnik, Margreet Lüchtenborg, Henrik Møller

Mortality Associated with Diabetes

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

Diabetes and Heart Disease

The Economic Impact and Cost-Effectiveness of Glucose Monitoring

Manage Your. Diabetes. Healthy Life. for a

Technology Assessment

Big Data Health Big Health Improvements? Dr Kerry Bailey MBBS BSc MSc MRCGP FFPH Dr Kelly Nock MPhys PhD

嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯

The Role of Insurance in Providing Access to Cardiac Care in Maryland. Samuel L. Brown, Ph.D. University of Baltimore College of Public Affairs

Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group

Treatment of diabetes In order to survive, people with type 1 diabetes must have insulin delivered by a pump or injections.

The Swedish approach: Quality Assurance with Clinical Quality Registries the RIKS-HIA example

Guidelines for the management of hypertension in patients with diabetes mellitus

Use of Glycated Hemoglobin and Microalbuminuria in the Monitoring of Diabetes Mellitus

MY TYPE 2 DIABETES NUMBERS

Multiple comorbidities: additive and predictive of cardiovascular risk. Peter M. Nilsson Lund University University Hospital Malmö, Sweden

St Lucia Diabetes and Hypertension Screening and Disease Management Programs

Australian heart disease statistics 2014

The American Cancer Society Cancer Prevention Study I: 12-Year Followup

Listen to your heart: Good Cardiovascular Health for Life

Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Athersclerotic Risk

Big Data for Population Health and Personalised Medicine through EMR Linkages

MEDICATION THERAPY ADHERENCE CLINIC : DIABETES

Prevalence of Diabetic Retinopathy: A Pilot Study from the SEARCH for Diabetes in Youth Study

FULL COVERAGE FOR PREVENTIVE MEDICATIONS AFTER MYOCARDIAL INFARCTION IMPACT ON RACIAL AND ETHNIC DISPARITIES

New Cholesterol Guidelines: Carte Blanche for Statin Overuse Rita F. Redberg, MD, MSc Professor of Medicine

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

4/9/2015. Risk Stratify Our Patients. Stroke Risk in AF: CHADS2 Scoring system JAMA 2001; 285:

Social inequalities in all cause and cause specific mortality in a country of the African region

4/9/2015. Opportunities for Making Type 2 Diabetes Prevention a Reality. Pat Schumacher, MS, RD. Objectives

Transcription:

School of Public Health University of Sydney Quantifying Life expectancy in people with Type 2 diabetes Alison Hayes School of Public Health University of Sydney

The evidence Life expectancy reduced by 8 years at age 40 (Roper et al BMJ 2001:322; 1389-1393 Life expectancy reduced by 5-12 years if diagnosed between 30-49 years; 2-5 years shorter if diagnosed at 50-69 years. Diabetes Natural History Study, Joslin Clinic 1939-1959, up to 25 year follow-up Schneider et al 29 year follow-up study, East Germany average patient age 63 years. Average loss of life expectancy 5.3 years (men) 6.4 years (women)

Hazard ratios by age and sex for all cause mortality for people with diabetes compared to no diabetes Mulnier et al Diabetic Medicine 2006 May;23(5):516-21.

Age standardized mortality rates of diabetic men and women compared with general population men women Gulliford and Charlton Am J Epidemiol 2009; 169:455-461

Conceptual Model School of Public Health University of Sydney R 3 R T2D 1 R 2 population Complications DEAD

Aspects of increased risk CVD risk is 2-4 times than of non-diabetic population Copenhagen heart study risk of having MI or stroke increased 2-3 fold, risk of death increased 2-fold (Almdal et al 2004) UK GP database - age adjusted risk of stroke 2.19 (diabetes/no diabetes) Mulnier et al 2006 MONICA project Perth in 1 year survivors of MI, HR death 2.5 (diabetes/no diabetes) (Briffa BMJ 2009) Diabetes associated with increased mortality after acute MI (HR 1.7). Mukamal et al Diabetes Care 2001

Risk factors for vascular events Age Sex Body mass index Smoking status Duration of diabetes Systolic blood pressure HbA1 c Total cholesterol : hdl ratio Prior clinical history Self rated health

Self rated health Cumulative hazard (%) 10 8 6 4 2 Vascular events p<0.001 0 0.0 0.5 1.0 1.5 2.0 2.5 Time (years) since EQ5D survey VAS <70 VAS 70 -<80 VAS 80 -<90 VAS >=90 Hayes et al, Diabetes Care 2008

Estimates of LE for Australians with diabetes Large prospective cohort study? Clinical trial data, e.g. ADVANCE, FIELD, UKPDS Registry data, NDR Administrative data e.g WA linked data Modelling

Trials vs administrative data Trial data Adjudicated outcomes (<1000 events) Detailed risk factor data (e.g. HbA1c measure) Selection criteria (generally healthier general population) Most trials do not have information on older patients Administrative data Outcomes identified through hospital admissions (1000s of events observed) Minimal risk factor data (e.g. age sex Whole population Include people of all ages

Population counts for Swedish & Australian data 30,000 WA data Swedish Registry Persons with diabetes 25,000 20,000 15,000 10,000 5,000 0 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85-89 UKPDS Age group FIELD ADVANCE

6,000 5,000 Trials vs admin data - numbers of Counts of events events WA data UKPDS Counts 4,000 3,000 2,000 1,000 0 MI stroke IHD Heart failure Amputation Renal failure Blindness Type of Complication

UKPDS outcomes model Discrete time simulation model Based on patient level data (n=3462) from UKPDS Predicts occurrence of major diabetes related complications and death Based on 20 years of data from 1977-97 Provides life expectancy and health economic outcomes Clarke et al Diabetologia. 2004; 47(10):1747-59

Components of UKPDS outcomes Model Epidemiological module Relate risk-factors to outcomes Non-fatal Outcomes; Diabetes-related deaths; Other deaths (competing risks) Risk factor time paths Predict risk factor values over time HbA1c Systolic Blood pressure Lipids Smoking Health Economic Outcomes Provide economic meaningful outcomes Event based costs Event based Utilities

Summary of UKPDS model equations Ischaemic Heart Disease (IHD) AGE 1.03 FEMALE 0.62 HbA1c 1.13 SBP 1.10 Ln (TOTAL:HDL) 4.47 (Eq.1, 231 events) Blindness (BLIND) AGE 1.07 HbA1c 1.25 (Eq. 6, 104 events) Renal failure (RENAL) SBP 1.50 BLIND 8.02 (Eq. 7, 24 events) Amputation (AMP) PVD 11.42 HbA1c 1.55 SBP 1.26 BLIND 6.12 (Eq. 5, 40 events ) Fatal and non-fatal Heart failure (CHF) AGE 1.10 myocardial infarction (MI) HbA1c 1.17 AGE 1.06 SBP 1.12 FEMALE 0.44 BMI 1.07 AC 0.27 (Eq. 3, n = 97) SMOK 1.41 HbA1c 1.13 SBP 1.11 Ln (TOTAL:HDL) 3.29 IHD 2.49 STROKE CHF 4.75 AGE 1.09 (Eq. 2, n = 495) FEMALE 0.60 SMOK 1.43 OTHER DEATH ATRFIB 4.17 HbA1c 1.12 (In force at all times) SBP 1.32 AGE FEMALE 1.08 TOTAL:HDL 1.12 AGE (1-FEMALE) 1.11 CHF 5.71 SMOK 1.36 (Eq. 4, n = 157) (Eq. 10, 250 deaths) Diabetes related mortality EVENT FATALITY (odds ratios) (In year of first event) DIABETES MORTALITY (In subsequent years) Ln (AGE_EVENT) 16.00 Ln (AGE_EVENT) 113.40 HbA1c 1.12 TOTAL:HDL 1.12 MI_EVENT 14.01 MI_EVENT 51.38 STROKE 2.85 MI_POST 3.06 RENAL AMP CHF 1.00 1.00 1.00 STROKE_EVENT 16.56 STROKE_POST 1.00 CHF 1.00 AMP 2.81 RENAL 4.88 (Eq. 8, 717 deaths) (Eq. 9, 100 deaths)

Risk models Probability of event in the next year conditional on survival to present time Risk of complications usually based on clinical risk factors, age, smoking Risk of death post event less dependent on clinical risk factors

Survival analysis 1.0 0.8 Survival 0.6 0.4 0.2 0.0 0 10 20 30 40 Years Median survival = 20.5 years Life expectancy = 19.7 years

Life expectancy tables Leal et al 2008. European Heart Journal epub 2008

Conceptual Model School of Public Health University of Sydney R 3 R T2D 1 R 2 population Complications DEAD

Post event survival Australian data WA administrative data set 70,340 persons with diabetes 10 years 1991-1999 Average 4.5 years follow-up Linked to death and hospital records 5 complications which elevate death MI, stroke, heart failure, amputation, renal failure Covariates age, sex, prior history

Kaplan Meier survival 0.00 0.25 0.50 0.75 1.00 Kaplan-Meier survival estimates 0 2 4 6 8 analysis time fspk = 1 fspk = 2 fspk = 3 fspk = 4 fspk = 5

Two-part model for death post event Logistic model for death within first month Gompertz model for survival post 1 month Covariates include age, sex, type of event, prior medical history

Survival post MI - men Survival 1.0 0.8 0.6 0.4 45 years 60 years 70 years 80 years 0.2 0.0-5 0 5 10 15 20 25 30 Time since event (years)

Survival post CHF - men Survival 1.0 0.8 0.6 0.4 45 years 60 years 70 years 80 years 0.2 0.0 0 10 20 30 Time since event (years)

Life expectancy estimates 1.0 0.8 80yr model 80yr 1month survivor Survival 0.6 0.4 0.2 0.0 0 10 20 30 Time (years) LE for 80 yr old immediately after MI = 2.6 years LE for 1 month survivors = 5.2 years

Continuing work Develop life expectancy tables following major diabetic complications Derive risk equation in suitable form to incorporate into UKPDS Risk tables based on clinical risk factors

Prediction is very difficult, especially if it is about the future Niels Bohr, Danish physicist 1922 Nobel Prizewinner

Acknowledgements NHMRC Research Grant Development and validation of an Australian Diabetes Health Policy Simulation Model Millennium Award DART Research Grant Development and validation of risk tables for quantifying life expectancy in people with type 2 diabetes